Related Experiment Video
Updated: Jul 23, 2025
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
Published on: March 7, 2017
Molecular Characterization and Treatment Approaches for Pediatric H3 K27-Altered Diffuse Midline Glioma: Integrated
Sudarshawn Damodharan1, Alexandra Abbott2, Kaitlyn Kellar2
1Department of Pediatrics, Division of Pediatric Hematology, Oncology and Bone Marrow Transplant, School of Medicine & Public Health, University of Wisconsin, Madison, WI 53792, USA.
Abstract:
Diffuse midline glioma (DMG), H3 K27-altered are highly aggressive, incurable central nervous system (CNS) tumors. The current standard palliative treatment is radiotherapy, with most children succumbing to the disease in less than one year from the time of diagnosis. Over the past decade, there have been significant advancements in our understanding of these heterogeneous tumors at the molecular level. As a result, most of the newer clinical trials offered utilize more targeted approaches with information derived from the tumor biopsy. In this systematic review, we used individual participant data from seven recent clinical trials published over the past five years that met our inclusion and exclusion criteria to analyze factors that influence overall survival (OS). We found that the most prominent genetic alterations H3.3 (H3F3A) and TP53 were associated with worse OS and that ACVR had a protective effect. In addition, re-irradiation was the only statistically significant treatment modality that showed any survival benefit. Our findings highlight some important characteristics of DMG, H3 K27-altered and their effects on OS along with the importance of continuing to review clinical trial data to improve our therapies for these fatal tumors.
Insights
Diffuse midline glioma (H3 K27-altered) survival is impacted by genetic alterations like H3.3 and TP53. Re-irradiation offers a survival benefit for these aggressive CNS tumors.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Clinical Trials
Background:
- Diffuse midline glioma (DMG), H3 K27-altered, are aggressive and incurable central nervous system tumors.
- Current treatment, radiotherapy, offers limited survival benefit, with most children succumbing within a year.
- Molecular understanding of these tumors has advanced, leading to targeted clinical trial approaches.
Purpose of the Study:
- To analyze factors influencing overall survival (OS) in H3 K27-altered DMG.
- To identify prognostic markers and effective treatment modalities from recent clinical trials.
- To inform future therapeutic strategies for these fatal pediatric brain tumors.
Main Methods:
- Systematic review of individual participant data from seven clinical trials.
- Inclusion of trials published within the last five years meeting specific criteria.
- Analysis of genetic alterations and treatment modalities impacting overall survival.
Main Results:
- H3.3 (H3F3A) and TP53 genetic alterations were associated with worse overall survival.
- ACVR (activin A receptor) demonstrated a protective effect on survival.
- Re-irradiation was the only statistically significant treatment modality showing a survival benefit.
Conclusions:
- Specific genetic alterations (H3.3, TP53) are key prognostic indicators in H3 K27-altered DMG.
- Re-irradiation presents a potential survival advantage for patients with these tumors.
- Continued analysis of clinical trial data is crucial for improving treatment outcomes for DMG, H3 K27-altered.
